Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Verducatib Formulations in Healthy Subjects
NCT06631417Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of verducatib in bronchiectasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point up to 22 days and Maximum measured concentration of the analyte in plasma up to 22 days. Started Oct 2024; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06631417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631417.